References
- Swinson RP. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51:35-41S
- Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005;62:1249-57
- Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;29;371:1115-25
- Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalised anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:1179-87
- Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 2008;9:248-312
- Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-6
- Nagata T, Suzuki F, Teo AR. Generalised social anxiety disorder: a still-neglected anxiety disorder 3 decades since Liebowitz’s review. Psychiatry Clin Neurosci. 2015;69:724-40
- Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-8
- Montgomery SA, Nil R, Dürr-Pal N, et al. A 24-week randomised, double-blind, placebo-controlled study of escitalopram for the prevention of generalised social anxiety disorder. J Clin Psychiatry 2005;66:1270-8
- ICH Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials 1998. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073137.pdf [Last accessed 12 December 2015]
- European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf [Last accessed 12 2015]
- Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 Evidence–based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 2010;12:471-7
- Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive–compulsive disorder: a revision of the 2005 guidelines from the British association for psychopharmacology. J Psychopharmacol 2014;28:403-39
- Sato H, Hirayasu Y. Escitalopram clinical pharmacokinetic study – single dose and multiple dose administration (Japan) [In Japanese]. Jpn J Clin Psychopharmacol 2011;14:839-55